Placeholder Banner

BIO Statement on Proposed Maryland Drug Pricing Legislation

January 10, 2017

Washington, D.C. (January 10, 2017) – The Biotechnology Innovation Organization today released the following statement regarding proposed drug pricing legislation within the Maryland Senate:

“Any legislative effort to address the affordability of medicines must be patient centered, holistic, and promote patient access to treatments and cures. Biotechnology innovation is not only providing enormous benefits to patients and value to the healthcare system, but it is a proven job creator, employing over 34,000 Marylanders in good, high-paying jobs, with billions invested in the state annually. BIO will oppose legislative proposals that could harm patient access to needed care by undermining competition, disrupting existing drug product availability, or stifling investment in the innovation ecosystem through heavy-handed government intrusion.”

###

Discover More
WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Chief of Global Health of the Biotechnology Innovation Organization (BIO), released the following statement on the loss of the United States’ measles elimination status.“The loss of…
Action plan outlines the policies needed to ensure that the biotechnology sector remains a driving force for America’s health, prosperity, national security, and geopolitical strengthWASHINGTON (November 10, 2026) - The Biotechnology Innovation…
Complaint argues HHS and CMS exceeded statutory authority; rule puts patient access, investment in future innovation, and America’s long-term biotechnology leadership at risk.WASHINGTON, DC & SAN DIEGO, CA & SAN FRANCISCO, CA - The…